Ge Lan’s Fund Imposes Purchase Limits Again After 4 Years

On August 9, to further ensure stable fund operation and protect the interests of fund shareholders, China Europe Medical Innovation, managed by star fund manager Ge Lan, announced a daily purchase limit of 100,000 yuan per account. According to the fund’s Q2 report, the combined size of its Class A and Class C shares reached 8.114 billion yuan as of June 30.

This year, the healthcare sector has seen a gradual uptrend, prompting Ge Lan’s China Europe Medical Innovation to impose purchase restrictions. The fund stated in its August 9 announcement that, to maintain stable operations and safeguard shareholder interests, starting August 11, subscriptions, transfers, and fixed-amount investments exceeding 100,000 yuan per day per account for any share class would be rejected.

As a fund manager specializing in healthcare investments, Ge Lan remains optimistic about the long-term prospects of the innovative drug sector. In the latest Q2 report, she emphasized maintaining a focus on the innovative drug and medical device supply chain. She cited two reasons: First, Chinese companies in fields like ADC, bispecific antibodies, and polypeptides are gaining global recognition, becoming key partners for multinational pharmaceutical pipelines, with several products expected to secure overseas licensing deals. Second, domestic policies continue to improve, supporting R&D efficiency, payment mechanisms, and smoother financing channels—all of which will further bolster innovative drug firms.

This year, China Europe Fund’s top-performing funds have frequently issued purchase restrictions. On August 9, China Europe Science and Technology Innovation Theme also capped subscriptions above 1 million yuan. Managed by Shao Jie, a member of the "China Europe Tech Team," the fund focuses on tech innovation and has delivered an 84.33% return over the past year as of August 8.

Similarly, Shao Jie’s China Europe Intelligent Manufacturing Hybrid Fund imposed a daily 100,000 yuan limit starting March 3. Meanwhile, Feng Ludan’s China Europe Digital Economy Fund suspended large subscriptions over 1 million yuan from August 6, having achieved over 140% returns in the past year. On May 19, Lan Xiaokang’s two funds—China Europe Value Return Hybrid and China Europe Dividend Enjoy Hybrid—set daily subscription caps at 2 million yuan.

Industry analysts note that as China’s mutual fund sector emphasizes high-quality development, firms are proactively limiting purchases during strong market periods. Scientifically controlling fund sizes helps maintain investment strategy effectiveness, ensures stable operations, and ultimately protects shareholder interests.

For instance, standout performers like Yongying Ruixin Hybrid, GF Growth Leading One-Year Holding Hybrid, and Nuon Duocelue Hybrid have also imposed purchase limits. Incomplete statistics show that since July, about 80 active equity funds have announced suspensions or large-purchase restrictions as of August 9.